Compare TCRX & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRX | BDSX |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 122.0M |
| IPO Year | 2021 | 2020 |
| Metric | TCRX | BDSX |
|---|---|---|
| Price | $1.15 | $18.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $8.00 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 490.6K | 150.1K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,325,000.00 | ★ $88,499,000.00 |
| Revenue This Year | N/A | $23.35 |
| Revenue Next Year | $69.75 | $19.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 266.65 | 24.08 |
| 52 Week Low | $0.88 | $0.25 |
| 52 Week High | $2.57 | $19.75 |
| Indicator | TCRX | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 73.17 |
| Support Level | $0.90 | $6.33 |
| Resistance Level | $1.23 | N/A |
| Average True Range (ATR) | 0.08 | 1.73 |
| MACD | 0.02 | 0.41 |
| Stochastic Oscillator | 62.41 | 89.10 |
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.